166 related articles for article (PubMed ID: 35177857)
1. Influenza virus infection history shapes antibody responses to influenza vaccination.
Auladell M; Phuong HVM; Mai LTQ; Tseng YY; Carolan L; Wilks S; Thai PQ; Price D; Duong NT; Hang NLK; Thanh LT; Thuong NTH; Huong TTK; Diep NTN; Bich VTN; Khvorov A; Hensen L; Duong TN; Kedzierska K; Anh DD; Wertheim H; Boyd SD; Good-Jacobson KL; Smith D; Barr I; Sullivan S; van Doorn HR; Fox A
Nat Med; 2022 Feb; 28(2):363-372. PubMed ID: 35177857
[TBL] [Abstract][Full Text] [Related]
2. Opposing Effects of Prior Infection versus Prior Vaccination on Vaccine Immunogenicity against Influenza A(H3N2) Viruses.
Fox A; Carolan L; Leung V; Phuong HVM; Khvorov A; Auladell M; Tseng YY; Thai PQ; Barr I; Subbarao K; Mai LTQ; van Doorn HR; Sullivan SG
Viruses; 2022 Feb; 14(3):. PubMed ID: 35336877
[TBL] [Abstract][Full Text] [Related]
3. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
4. Effects of Repeated Annual Inactivated Influenza Vaccination among Healthcare Personnel on Serum Hemagglutinin Inhibition Antibody Response to A/Perth/16/2009 (H3N2)-like virus during 2010-11.
Thompson MG; Naleway A; Fry AM; Ball S; Spencer SM; Reynolds S; Bozeman S; Levine M; Katz JM; Gaglani M
Vaccine; 2016 Feb; 34(7):981-8. PubMed ID: 26813801
[TBL] [Abstract][Full Text] [Related]
5. Impact of Immune Priming, Vaccination, and Infection on Influenza A(H3N2) Antibody Landscapes in Children.
Hinojosa M; Shepard SS; Chung JR; King JP; McLean HQ; Flannery B; Belongia EA; Levine MZ
J Infect Dis; 2021 Aug; 224(3):469-480. PubMed ID: 33090202
[TBL] [Abstract][Full Text] [Related]
6. An updated influenza A(H3N2) vaccine generates limited antibody responses to previously encountered antigens in children.
Florek KR; Campos LM; Braun KM; McLean HQ; King JP; Flannery B; Belongia EA; Friedrich TC
Vaccine; 2018 Jan; 36(5):758-764. PubMed ID: 29249543
[TBL] [Abstract][Full Text] [Related]
7. Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons.
Hiroi S; Morikawa S; Nakata K; Maeda A; Kanno T; Irie S; Ohfuji S; Hirota Y; Kase T
Hum Vaccin Immunother; 2015; 11(2):386-90. PubMed ID: 25692378
[TBL] [Abstract][Full Text] [Related]
8. Serologic response to sequential vaccination with enhanced influenza vaccines: Open label randomized trial among adults aged 65-74 years.
McLean HQ; Levine MZ; King JP; Flannery B; Belongia EA
Vaccine; 2021 Dec; 39(49):7146-7152. PubMed ID: 34774360
[TBL] [Abstract][Full Text] [Related]
9. Differential Effects of Prior Influenza Exposures on H3N2 Cross-reactivity of Human Postvaccination Sera.
Xie H; Li L; Ye Z; Li X; Plant EP; Zoueva O; Zhao Y; Jing X; Lin Z; Kawano T; Chiang MJ; Finch CL; Kosikova M; Zhang A; Zhu Y; Wan XF
Clin Infect Dis; 2017 Jul; 65(2):259-267. PubMed ID: 28369230
[TBL] [Abstract][Full Text] [Related]
10. A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.
Yang JR; Cheng CY; Chen CY; Lin CH; Kuo CY; Huang HY; Wu FT; Yang YC; Wu CY; Liu MT; Hsiao PW
Antiviral Res; 2017 Apr; 140():62-75. PubMed ID: 28093338
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis.
Ruiz-Palacios GM; Leroux-Roels G; Beran J; Devaster JM; Esen M; Launay O; McElhaney JE; van Essen GA; Benoit A; Claeys C; Dewé W; Durand C; Duval X; Falsey AR; Feldman G; Galtier F; Gervais P; Hwang SJ; McNeil S; Richardus JH; Trofa A; Oostvogels L;
Hum Vaccin Immunother; 2016 Dec; 12(12):3043-3055. PubMed ID: 27690762
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of the antibody response to seasonal influenza vaccination among the elderly.
Kositanont U; Assantachai P; Wasi C; Puthavathana P; Praditsuwan R
Viral Immunol; 2012 Dec; 25(6):471-6. PubMed ID: 23061793
[TBL] [Abstract][Full Text] [Related]
13. Influence of pre-existing hemagglutination inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50-80 years of age.
Ross TM; Lin CJ; Nowalk MP; Huang HH; Spencer SM; Shay DK; Sambhara S; Sundaram ME; Friedrich T; Sauereisen S; Bloom CE; Zimmerman RK
Hum Vaccin Immunother; 2014; 10(5):1195-203. PubMed ID: 24614078
[TBL] [Abstract][Full Text] [Related]
14. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season.
Ganczak M; Dubiel P; Drozd-Dąbrowska M; Hallmann-Szelińska E; Szymański K; Brydak LB
Int J Environ Res Public Health; 2019 Nov; 16(22):. PubMed ID: 31739554
[TBL] [Abstract][Full Text] [Related]
15. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
16. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.
Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial to assess immunogenicity of high-dose, adjuvanted, and recombinant influenza vaccines against cell-grown A(H3N2) viruses in adults 65 to 74 years, 2017-2018.
Belongia EA; Levine MZ; Olaiya O; Gross FL; King JP; Flannery B; McLean HQ
Vaccine; 2020 Mar; 38(15):3121-3128. PubMed ID: 32145994
[TBL] [Abstract][Full Text] [Related]
18. Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine.
Shinde V; Cai R; Plested J; Cho I; Fiske J; Pham X; Zhu M; Cloney-Clark S; Wang N; Zhou H; Zhou B; Patel N; Massare MJ; Fix A; Spindler M; Thomas DN; Smith G; Fries L; Glenn GM
Clin Infect Dis; 2021 Dec; 73(11):e4278-e4287. PubMed ID: 33146720
[TBL] [Abstract][Full Text] [Related]
19. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.
Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710
[TBL] [Abstract][Full Text] [Related]
20. A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.
Gorse GJ; Grimes S; Buck H; Mulla H; White P; Hill H; May J; Frey SE; Blackburn P
Vaccine; 2022 Feb; 40(9):1271-1281. PubMed ID: 35125219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
